Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $372,346.54 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 4,847 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $372,346.54. Following the completion of the sale, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $10,835,691.46. The trade was a 3.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Revolution Medicines Stock Up 3.7%

Shares of RVMD opened at $78.78 on Friday. The stock has a market cap of $15.23 billion, a price-to-earnings ratio of -15.24 and a beta of 0.96. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $81.49. The company has a 50-day moving average price of $66.73 and a two-hundred day moving average price of $49.27.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the prior year, the company posted ($0.94) earnings per share. Equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on RVMD shares. Needham & Company LLC lifted their price objective on Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, November 6th. The Goldman Sachs Group lifted their price target on shares of Revolution Medicines from $65.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 12th. HC Wainwright upped their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Wolfe Research initiated coverage on Revolution Medicines in a report on Tuesday, November 18th. They issued an “outperform” rating and a $75.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $78.50.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors have recently modified their holdings of the stock. Farallon Capital Management LLC grew its stake in shares of Revolution Medicines by 2.1% during the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after purchasing an additional 300,000 shares during the last quarter. Baker BROS. Advisors LP raised its position in Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock worth $441,565,000 after purchasing an additional 90,385 shares during the last quarter. Nextech Invest Ltd. lifted its holdings in Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its position in Revolution Medicines by 2.1% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company’s stock valued at $290,628,000 after buying an additional 130,000 shares during the last quarter. Finally, Bellevue Group AG boosted its position in Revolution Medicines by 21.7% in the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock valued at $260,298,000 after buying an additional 994,538 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Key Stores Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.